TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15934094
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500 mg/day)
Study: 14615670
Drug: Effective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective treatment of GERD with prolonged and aggressive antisecretory therapy
Study: 10387955
Drug: Ibuprofen with
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen with organic acids as excipients in enteric matrix granules (Eudragit S and Aqoat AS-HF)
Study: 10387955
Drug: Bioavailability tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioavailability tests
Study: 10387955
Drug: Mathematical transformation
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mathematical transformation of data for individual formulations
Study: 7201812
Drug: Bronchoretard (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoretard (350 mg theophylline in capsule)
Study: 22350624
Drug: Clopidogrel pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel pre-treatment within 5 days prior to surgery
Study: 17173912
Drug: RF-NaP (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: RF-NaP (32 tablets, split dosing, 4 every 15 minutes)
Study: 17173912
Drug: RF-NaP (28
Approvals — FDA: no, EMA: no, PMDA: no
Description: RF-NaP (28 tablets, split dosing, 4 every 15 minutes)
Study: 15179409
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g Hypericum powder with comparable hyperforin content
Study: 11472387
Drug: Metamizol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol 0.5 g
Study: 23545707
Drug: losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 100 mg daily
Study: 16432441
Drug: Comparison conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison conditions (routine care or another treatment)
Study: 11081322
Drug: Trimetazidine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (3 x 20 mg/day for 24 hours prior to exercise test)
Study: 15995772
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug administered)
Study: 9121852
Drug: Budesonide 600
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 600 mu g twice daily
Study: 1537130
Drug: Pimobendan 5
Normalized name: pimobendan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan 5 mg/day
Study: 1537130
Drug: Pimobendan 10
Normalized name: pimobendan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan 10 mg/day
Study: 1537130
Drug: Pimobendan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan (all doses combined)
Study: 6714792
Drug: Cyclotropium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclotropium bromide (60 mg)
Study: 6714792
Drug: Hyoscine N-butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N-butylbromide (60 mg)
Study: 29327602
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) with 2000 shock waves at 0.02 mJ/mm2 for 3 sessions, once a week.
Study: 26823210
Drug: FF 100
Normalized name: APAP 325/CAFF 100/ISOMETHEPTENE 65MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF 100 μg in the morning (AM)
Study: 26823210
Drug: FF 100
Normalized name: APAP 325/CAFF 100/ISOMETHEPTENE 65MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF 100 μg in the evening (PM)
Study: 21040188
Drug: Slow up-titration
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow up-titration with paroxetine (increments of 2.5 mg/day every 2 days)
Study: 18949779
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil in combination with prednisone
Study: 16288373
Drug: HPV-6 L2E7
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-6 L2E7 vaccine with AS02A adjuvant
Study: 11923135
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment variation
Study: 28272808
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment for HF
Study: 26275648
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg/day, up titrated to 2 g/day
Study: 23852294
Drug: Polyherbal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyherbal formulation (PHF)
Study: 23811465
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine treatment
Study: 8770380
Drug: Bronchoconstriction provoked
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchoconstriction provoked by allergic agents
Study: 1308247
Drug: 75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/kg Triclofos elixir (Regimen I)
Study: 29500585
Drug: Oxazepam 10
Normalized name: oxazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 10 mg (OXA10)
Study: 29500585
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg (DIA10)
Study: 29500585
Drug: Oxazepam 30
Normalized name: oxazepam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 30 mg (OXA30)
Study: 16194202
Drug: Ximelagatran (24-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (24-60 mg b.i.d)
Study: 11807406
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for X‐linked severe combined immunodeficiency (SCID‐X1)
Study: 1686339
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tetrazepam and a nonsteroid analgetic
Study: 26347428
Drug: Language for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Language for Learning intervention (18 1-hour home-based therapy sessions)
Study: 23472619
Drug: 20-mg memantine
Normalized name: memantine hydrochloride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg memantine
Study: 7941992
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment (external beam photon treatment of the whole pelvis, average total dose of 3680 cGy rad)
Study: 31578771
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once daily for 6 weeks
Study: 10570555
Drug: Topical terbinafine
Normalized name: terbinafine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical terbinafine
Study: 11682403
Drug: Remifentanil 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 10 microg plus propofol 5 mg
Study: 9322450
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 80 mg/kg intravenously in divided doses
Study: 3361096
Drug: Training group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training group that received formal instructions in principles underlying figural relations problem solution (n = 24)
Study: 30928180
Drug: 40IU intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40IU intranasal oxytocin
Study: 19230772
Drug: Azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (75 mg/m² per day for 7 days every 28 days)
Study: 19230772
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy)
Study: 17029304
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml 0.9% saline (placebo)
Study: 10947034
Drug: Melatonin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (0.1 mg)
Study: 11422884
Drug: Melatonin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (all doses)
Study: 25387601
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus chemotherapy (armA)
Study: 23228201
Drug: Lithium 0.6‐1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium 0.6‐1.2 mEq/L
Study: 23228201
Drug: Lithium <0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium <0.6 mEq/L
Study: 18245031
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) internet intervention
Study: 16155359
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E supplementation (600 mg/day)
Study: 12882653
Drug: NRTI-only therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI-only therapy
Study: 10371242
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg triazolam (Halcion)
Study: 1675865
Drug: Pamidronate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate treatment (n = 76)
Study: 6347278
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + cyclophosphamide (C) for 12 monthly cycles
Study: 6347278
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + cyclophosphamide/methotrexate/5‐fluorouracil (CMF) for 12 monthly cycles
Study: 19328435
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg b.i.d. celecoxib (Celebrex, Pfizer)
Study: 19328435
Drug: 220 mg
Normalized name: urea 220 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 220 mg b.i.d. naproxen sodium (Aleve, Bayer)
Study: 6367553
Drug: Verapamil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (10 mg)
Study: 28820468
Drug: Resveratrol 19.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 19.8 mg with Pegylated-Interferon-α2b and Ribavirin
Study: 19496898
Drug: Twice-daily application
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily application of 0.1% tacrolimus
Study: 16330464
Drug: Combined antiplatelet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antiplatelet plus moderate intensity anticoagulant therapy
Study: 12627304
Drug: Concurrent strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent strength and endurance training (SE)
Study: 6712367
Drug: Spironolactone therapy
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone therapy for two to four months
Study: 6712367
Drug: Chlorthalidone treatment
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone treatment
Study: 27923550
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg I.V. every 2 weeks for up to 1 year
Study: 27923550
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m2 I.V. on days 1, 8, 29, and 36
Study: 25916335
Drug: Proprietary nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary nutritional supplement containing magnesium, riboflavin and Q10
Study: 19282313
Drug: Rate control
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate control (beta blockers and/or digoxin to reduce heart rate to <80 bpm at rest and <110 bpm after walking)
Study: 15484727
Drug: Rapeseed meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed meal diet (200 g/kg)
Study: 28270229
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg every 4 months for five doses)
Study: 21566547
Drug: Skin protection
Normalized name: NeutrapHor 1% Skin Protection Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin protection cream containing glycerol, vaseline, and liquid paraffin, applied twice a day
Study: 21566547
Drug: Vaseline ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaseline ointment, applied twice a day
Study: 16513607
Drug: Dynamic 18F‐FET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic 18F‐FET PET studies (0‐40 min after injection of 180 MBq of 18F‐FET)
Study: 15351769
Drug: Topiramate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (25 mg/d to 300 mg/d)
Study: 8229497
Drug: Chlorpromazine plus
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine plus lorazepam (30 mg/m2 chlorpromazine and 0.04 mg/kg lorazepam, both given intravenously)
Study: 21464363
Drug: Low alcohol
Normalized name: Low alcohol beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low alcohol dose (0.4 g/kg)
Study: 30946883
Drug: High alcohol
Normalized name: High alcohol lager
Approvals — FDA: no, EMA: no, PMDA: no
Description: High alcohol dose (0.6 g/kg)
Study: 17719311
Drug: Beta-blockers (maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (maximal tolerated doses)
Study: 10340913
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg/day, administered for 21 days)
Study: 29171468
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/day (Group 1)
Study: 29171468
Drug: Gliclazide MB
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide MB 60 mg/day (Group 2)
Study: 25948124
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus yangxinkang tablets for 4 weeks
Study: 25948124
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western treatment (Control)
Study: 14585880
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (800 microg)
Study: 6724715
Drug: Cimetidine (histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (histamine H2-receptor blocker)
Study: 24052362
Drug: Ivabradine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (15 mg)
Study: 29982532
Drug: fractional-dose IPV
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fractional-dose IPV (fIPV)
Study: 15696331
Drug: BCAA/TRP mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA/TRP mixture (60 g BCAA and 2 g TRP)
Study: 7933535
Drug: Antibiotic plus
Normalized name: Triple Antibiotic Plus
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic plus fluconazole therapy (FLCZ group)
Study: 7933535
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy only (antibiotic group)
Study: 9952150
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.5 mg
Study: 24252674
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate (500 ml administered 2-3 hours before anesthesia)
Study: 24252674
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (500 ml administered 2-3 hours before anesthesia)
Study: 10568558
Drug: Pacemaker therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacemaker therapy
Study: 12685882
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily for 2 weeks
Study: 12685882
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily for 4 weeks
Study: 10574419
Drug: Irbesartan 75
Normalized name: irbesartan 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 75 mg/HCTZ 12.5 mg
Study: 18633426
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/HCTZ 12.5 mg
Study: 8908379
Drug: Glimepiride 4
Normalized name: glimepiride 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 4 mg twice daily (b.i.d.)
Study: 8908379
Drug: Glimepiride 16
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride 16 mg once daily (q.d.)
Study: 8908379
Drug: Glimepiride 8
Normalized name: glimepiride 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 8 mg twice daily (b.i.d.)
Study: 6135720
Drug: Estazolam 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam 2.0 mg
Study: 17293731
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg twice daily
Study: 24926075
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy plus acupuncture for 3 months
Study: 24926075
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination therapy
Study: 19639415
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel (60, 90 or 120 mg)
Study: 15975126
Drug: Stabilization splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilization splint therapy (Group I)
Study: 12689686
Drug: Ibandronate 2.5
Normalized name: ibandronate 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 2.5 mg taken 30 minutes before breakfast
Study: 8528172
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow examination 2 weeks post-infusion
Study: 25276626
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation along with regular medicine
Study: 21316541
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of nevirapine 200-mg tablet
Study: 12442030
Drug: rG-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rG-CSF (5 microg/kg/dose i.v. twice a day)
Study: 12442030
Drug: rhuGM-CSF (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuGM-CSF (4 microg/kg/dose i.v. twice a day)
Study: 31336101
Drug: tablet gaming
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet gaming control
Study: 28532408
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) administered at 2 days and 1 year postoperatively
Study: 23392737
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin treatment
Study: 11421880
Drug: Omeprazole group
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole group (20 mg b.d. for 7 days + 14 days additional therapy with omeprazole 20 mg)
Study: 11421880
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (7 days triple therapy + placebo for 14 days)
Study: 9137798
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 160 mg/day
Study: 7970504
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 800 mg/day
Study: 7970505
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 1280 mg/day
Study: 11019429
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg (three times a day)
Study: 23134097
Drug: Post-discharge warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discharge warfarin management service with pharmacist education during two or three home visits.
Study: 10191137
Drug: Melatonin 2.5
Normalized name: melatonin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 2.5 mg
Study: 8564107
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 1.5 mg inhaled daily for 8 weeks
Study: 3537268
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline sulfate (0.25 mg) administered to 43/85 (50.5%) of ECV candidates
Study: 20865240
Drug: Sulodexide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (200 mg/day)
Study: 18000175
Drug: Risk score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk score additionally dependent on a decreased first‐phase insulin response variable from intravenous glucose tolerance tests (IVGTTs)
Study: 21498906
Drug: Atorvastatin (10mg/day)
Normalized name: atorvastatin 10 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (10mg/day)
Study: 21376564
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil patient-controlled analgesia
Study: 10799352
Drug: Kamillosan(R) cream
Normalized name: pantolactone, (R)-
DrugBank: Levomenol (DB13153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kamillosan(R) cream
Study: 8582464
Drug: 0.5% hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hydrocortisone cream
Study: 11369904
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (placebo)
Study: 9277559
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium intake (1,800 mg/day)
Study: 9277559
Drug: Control calcium
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control calcium intake (800 mg/day)
Study: 26469356
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus casei Shirota (LcS), administered twice daily for 8 weeks